2008-07-04 20:37:18 - www.companiesandmarkets.com adds new report - Theratechnologies Inc - Premium Company Profile

www.companiesandmarkets.com/Summary-Company-Profile/Theratechnol ..
Introduction

Theratechnologies is a Canadian biopharmaceutical company developing therapeutic peptides for endocrine and metabolic disorders. The company has developed its product pipeline utilizing two technologies ExoPep and LAP (Long Acting Peptide).



Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/

partners, shareholding structure and key employees with biographies


Highlights

The company’s pipeline products include: TH9507 being developed for HIV-Associated Lipodystrophy (Phase III); ThGRF being developed for growth hormone deficiency (Phase I), and cystic fibrosis (Phase I); and THG213.29 being developed for renal disease (preclinical).



The company recognizes revenues in the form of royalties, and interest on investments from other pharmaceutical/biotechnology companies like ALZA pursuant to its co-development agreements.



The company’s total revenues declined at a CAGR of 33.8% from $7.6 million to $1.5 million during the period 2002-2006. This represents an absolute decline of -$6.1 million for the period of analysis. The company derived its revenues from royalties, and interest on investments.



Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company’s adjusted five year financial data along with key ratios and market capitalization